Insilico teams up with US firm to build AI models predicting disease decades ahead
Tie-up combines Hong Kong-listed Insilico Medicine’s algorithms with Human Longevity’s genomic data to advance personalised health research
The partnership was announced as the global longevity market, fuelled by an ageing population and rising consumption demand, was valued at about US$5.3 trillion and projected to reach US$8 trillion by 2030, according to a recent UBS report.
Insilico founder and CEO Alex Zhavoronkov, in a written reply, framed the tie-up as the world’s two leading companies in the AI and longevity fields joining forces, adding they “have developed a conceptually new type of personal longevity AI that will not only let you live longer, but also help you and others discover new longevity drugs that work for everyone.”
Neither party disclosed the exact investment amount. They described the arrangement as “a multimillion-dollar AI co-development collaboration”.
Shares of Insilico declined 4.21 per cent to HK$48.28 apiece on Tuesday and slipped a further 0.4 per cent to HK$48.10 on Wednesday. The company raised HK$2.28 billion (US$291 million) in its initial public offering in December. Its self-developed AI platform spans the entire drug discovery process, from identifying disease targets to designing drug candidates and predicting clinical outcomes.
The collaboration will be executed through Human Life Foundation Models (HLFM), a newly launched company set up by Human Longevity.